Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6141883 | 0.92 | PTGS2 (0.47) | KMT2AGAACA1CA2CA12 | |
| SCHEMBL4861850 | 0.92 | PTGS2 (0.47) | KMT2AGAACA1CA2CA12 | |
| SCHEMBL7239883 | 0.90 | PTGS2 (0.47) | CA1CA2CA12CA9PTGS2 | |
| SCHEMBL4854600 | 0.87 | ALDH1A1 (0.55) | KMT2AGAAKDM4EALDH1A1RXFP1 | |
| SCHEMBL4854567 | 0.85 | KDM4E (0.48) | KMT2AKDM4EALDH1A1RXFP1LMNA | |
| SCHEMBL4864177 | 0.84 | KDM4E (0.49) | KMT2AGAAKDM4EALDH1A1RXFP1 | |
| SCHEMBL4862273 | 0.82 | ALDH1A1 (0.52) | KMT2AGAACA1CA2KDM4E | |
| SCHEMBL6141903 | 0.82 | GAA (0.49) | KMT2AGAACA1CA2CA12 | |
| SCHEMBL4859624 | 0.82 | PTGS2 (0.46) | KMT2AGAAPTGS2KDM4EALDH1A1 | |
| SCHEMBL6141813 | 0.80 | PTGS2 (0.51) | PTGS2KDM4EPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1492774-A2 | PYRIMIDONE DERIVATIVES USEFUL FOR THE TREATMENT OF INFLAMMATION AND IMMUNOLOGICAL DISEASES | Orchid Chemicals and Pharmaceuticals Ltd (IN) | 2005-01-05 | — | — | EP | claimed |
| US-20030225075-A1 | Novel pyrimidone derivatives | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2003-12-04 | — | — | US | claimed |
| WO-2003084938-A2 | PYRIMIDONE DERIVATIVES USEFUL FOR THE TREATMENT OF INFLAMMATIN AND IMMUNOLOGICAL DISEASES | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2003-10-16 | — | — | WO | claimed |
| EP-1492774-A2 | PYRIMIDONE DERIVATIVES USEFUL FOR THE TREATMENT OF INFLAMMATION AND IMMUNOLOGICAL DISEASES | Orchid Chemicals and Pharmaceuticals Ltd (IN) | 2005-01-05 | — | — | EP | disclosed |
| US-20030225075-A1 | Novel pyrimidone derivatives | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2003-12-04 | — | — | US | disclosed |
| WO-2003084938-A2 | PYRIMIDONE DERIVATIVES USEFUL FOR THE TREATMENT OF INFLAMMATIN AND IMMUNOLOGICAL DISEASES | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225075-A1 | Novel pyrimidone derivatives | TPMT, TYMP, TYMS | KMT2A 4314/4885GAA 2140/4885CA1 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.